Intralesional methotrexate treatment for keratoacanthoma tumors: a retrospective case series.
Intralesional methotrexate (IL-MTX) is an effective treatment for keratoacanthoma. We sought to determine the response rates and adverse events in KA treated with intralesional methotrexate. All cases of KA treated with intralesional methotrexate at our institutions from 2001 to 2009 were systematically reviewed. Forty-six cases of KA treated with IL-MTX were identified. A complete resolution was achieved in 74% of patients, requiring an average of 1.8 injection sessions, for a mean total dose of 10 mg. Adverse events did not occur. The follow-up period was short, and there was no histologic confirmation of the initial diagnosis. IL-MTX is an effective and well-tolerated alternative to surgery for the treatment of KA.